BriaCell Therapeutics Has Received Approval From FDA On Its Pivotal Registrational Study Design For Bria-IMT In Combination With A Checkpoint Inhibitor In Advanced Metastatic Breast Cancer; Patient Recruitment And Dosing Will Commence In the Summer of 202
Portfolio Pulse from Benzinga Newsdesk
BriaCell Therapeutics has received FDA approval for its pivotal registrational study design for Bria-IMT in combination with a checkpoint inhibitor in advanced metastatic breast cancer. Patient recruitment and dosing will commence in the summer of 2022.
June 27, 2023 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BriaCell Therapeutics has received FDA approval for its Bria-IMT study in advanced metastatic breast cancer, with patient recruitment and dosing starting in summer 2022.
The FDA approval for BriaCell's pivotal registrational study design is a significant milestone for the company, as it allows them to proceed with patient recruitment and dosing. This positive news is likely to have a short-term positive impact on BCTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100